Biohaven Ltd. Net Change in Cash
Biohaven Ltd. (BHVN) reported Net Change in Cash of $7.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-10
- Biohaven Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $44.33M, a 30053.74% increase year-over-year.
- Biohaven Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $147.00K.
- Biohaven Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$65.19M.
- Biohaven Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$52.01M.
- Biohaven Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $130.24M.
- Biohaven Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$149.58M, a 1671.86% decline from fiscal 2023.
- Biohaven Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $9.52M, a 94.25% decline from fiscal 2022.
- Biohaven Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $165.55M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.85M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $44.33M 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $130.24M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $85.84M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $66.45M 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | $147.00K 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -$149.58M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | -$164.10M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | -$9.80M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | -$65.19M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $9.52M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$116.61M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$40.65M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | -$52.01M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $165.55M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | -$25.64M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$53.10M 10-Q · filed 2023-07-31 | |||
| 2022-03-31 | -$36.05M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$6.45M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $279.19M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $73.59M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |